CDK2, or cyclin-dependent kinase 2, plays a crucial role in regulating the cell cycle, particularly in the transition from the G1 phase to the S phase. Its application is primarily focused in the field of cancer research and therapy. By targeting CDK2, researchers aim to develop inhibitors that can halt the uncontrolled proliferation of cancer cells. These inhibitors are being explored as potential treatments for various cancers, including breast, ovarian, and lung cancers. Additionally, CDK2 is studied in the context of drug resistance, as its inhibition may help overcome resistance to other cancer therapies. Beyond oncology, CDK2 is also investigated in the context of neurodegenerative diseases, where its regulation might influence neuronal survival and function. Overall, CDK2 is a significant target for developing therapeutic strategies aimed at controlling cell cycle dysregulation in various diseases.